Daniel Schultz’s 15-year run at the Food & Drug Administration’s medical device division is coming to an end, the Wall Street Journal reported.
Resigning from his post as head of FDA’s Center for Devices and Radiological Health “by mutual agreement” with new FDA commissioner Margaret Hamburg, Schultz wrote a letter to his soon-to-be-ex-employees saying he decided to end his five years as CDRH’s leader “based on discussions with Commissioner Hamburg.”
His tenure was controversial, as Schultz has faced broadsides in Congress and from doctors and scientists within his own organization upset that their expertise and opinions were being ignored in favor of industry interests.
